에서 실시간으로 운영 중이에요! 자세히 알아보기
KOD 아이콘

Kodiak Sciences
KOD

85.75 USD
-2.37
2.69%
장 마감 시점 업데이트됨 10월 16일 PM 4:00 EDT
프리마켓
시간외 거래
85.00
-0.75
0.87%
1일
-2.69%
5일
-14.32%
1개월
161.67%
3개월
107.88%
6개월
112.2%
연초 이후
229.55%
1년
474.73%
5년
-23.28%
10년
744%
 

소개: Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.

직원 수: 124

건강관리 생명공학

뉴스

긍정적
중립
부정적
투자 심리 3개월
긍정적 40%
중립 50%
부정적 10%
중립
Schaeffers Research
4일 전
11 Stocks Most Likely to See a Short Squeeze Rally
Bond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors heading into earnings season.
11 Stocks Most Likely to See a Short Squeeze Rally
중립
PRNewsWire
9일 전
Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026
First scientific presentation of Phase 3 DAYBREAK results for Zenkuda and tabirafusp-ted in wet age-related macular degeneration scheduled for AAO 2026. Additional presentations include Phase 3 GLOW2 data for Zenkuda in diabetic retinopathy and Phase 1b APEX data for KSI-101 in macular edema secondary to inflammation (MESI).
Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026
부정적
Benzinga
11일 전
Top 3 Health Care Stocks That May Collapse In Q4
As of Oct. 5, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Top 3 Health Care Stocks That May Collapse In Q4
중립
MarketBeat
14일 전
Kodiak Sciences' Two Wet AMD Treatments Match Aflibercept in Phase III Study
Kodiak Sciences NASDAQ: KOD reported that its Phase III DAYBREAK study met primary endpoints for two investigational treatments in treatment-naïve patients with wet age-related macular degeneration, or wet AMD, with both therapies demonstrating statistical equivalence to aflibercept on visual-acuity outcomes.
Kodiak Sciences' Two Wet AMD Treatments Match Aflibercept in Phase III Study
부정적
24/7 Wall Street
16일 전
A $32 Biotech Became a $90 Biotech Overnight. Is It Too Late to Buy Kodiak?
Kodiak Sciences tripled in a single session after its eye drug cleared a pivotal trial, but a cash-burning biotech with no revenue and a likely share offering complicates any case for chasing the move.
A $32 Biotech Became a $90 Biotech Overnight. Is It Too Late to Buy Kodiak?
긍정적
Zacks Investment Research
17일 전
KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears
Kodiak surges 178% as positive phase III DAYBREAK data show Zenkuda and tabirafusp-ted met key endpoints against Eylea.
KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears
긍정적
The Motley Fool
18일 전
Why Kodiak Sciences Skyrocketed Today
Zenkuda and KSI-501 achieved their primary goals in a Phase 3 study. The global market for retinal drugs could exceed $32 billion by the end of the decade.
Why Kodiak Sciences Skyrocketed Today
중립
Seeking Alpha
18일 전
Kodiak Sciences Inc. (KOD) Discusses DAYBREAK Topline Data and Primary Endpoint Results Transcript
Kodiak Sciences Inc. (KOD) Discusses DAYBREAK Topline Data and Primary Endpoint Results Transcript
Kodiak Sciences Inc. (KOD) Discusses DAYBREAK Topline Data and Primary Endpoint Results Transcript
긍정적
Proactive Investors
18일 전
Kodiak Sciences soars as Zenkuda, tabirafusp-ted hit primary endpoints in phase III wet AMD trial
Kodiak Sciences Inc (NASDAQ:KOD) surged after Zenkuda and tabirafusp-ted met their primary endpoints in the phase III DAYBREAK trial for wet age-related macular degeneration. Shares gained over 162% by midday Monday following the announcement.
Kodiak Sciences soars as Zenkuda, tabirafusp-ted hit primary endpoints in phase III wet AMD trial
긍정적
Benzinga
18일 전
Kodiak Sciences Says Eye Drug on Par with Regeneron's Medicine
Kodiak Sciences Inc. (NASDAQ:KOD) on Monday released data from the Phase 3 DAYBREAK trial for patients suffering from wet age-related macular degeneration (wAMD).
Kodiak Sciences Says Eye Drug on Par with Regeneron's Medicine
뉴스 순위 보기
Lightweight Charts™를 사용해 가격 차트를 구현했어요.